Cytomegalovirus (CMV) infection is the most common viral infection in liver transplant
recipients, affecting post-transplant patients and graft survival. Recent advances in …

BACKGROUND: The incidence of cytomegalovirus (CMV) syndrome/disease after adult
solid organ transplantation in the era effective antiviral therapy has not been fully assessed …

AA Boudreault, H. Xie, RM Rakita, JD Scott, CL Davis, M. Boeckh, AP Limaye. Risk factors
for late‐onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney …

Introduction Cytomegalovirus (CMV) causes significant morbidity in solid organ transplant
recipients (SOTR). Measuring cell‐mediated immunity (CMI) may inform the risk of CMV …

The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus
(CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient …

Background Valganciclovir, the oral prodrug of ganciclovir, has been demonstrated
equivalent to iv ganciclovir for CMV disease treatment in solid organ transplant recipients …

Background Cytomegalovirus (CMV) is the most common opportunistic infection after solid-
organ transplantation, increasing morbidity and mortality. Three months of oral …

Background The use of assays detecting cytomegalovirus (CMV)–specific T cell–mediated
immunity may individualize the duration of antiviral prophylaxis after transplantation …

Cytomegalovirus (CMV) is one of the most important pathogens following solid-organ
transplantation, and effective prevention of CMV infection is a priority. The long-term control …

Cytomegalovirus (CMV) is a major cause of morbidity and mortality following solid organ
transplantation (SOT). Two strategies, prophylactic, and preemptive have emerged for the …